An independent, freely accessible educational resource on glucagon-like peptide-1 receptor agonists — covering pharmacology, clinical evidence, prescribing, and safety.
Content referenced against published clinical guidelines and trial data
Who We Are
GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and dulaglutide — have substantially changed how type 2 diabetes and obesity are managed. The evidence base from landmark trials (LEADER, SUSTAIN-6, SELECT, STEP 1–5, SURPASS 1–5, PIONEER, FLOW) is large and rapidly evolving.
This is an independent educational resource. All content is referenced against published SmPCs, NICE guidelines, and peer-reviewed literature. It is not affiliated with, endorsed by, or recognised by any NHS organisation, pharmaceutical company, or regulatory body.
Read our full storyLearning Modules
Fourteen structured modules covering everything from molecular mechanisms to real-world prescribing.
GLP-1R → Gαs → ↑cAMP → K-ATP closure → Ca²⁺ influx → glucose-dependent insulin secretion. Pancreatic, cardiovascular, renal, neural, and hepatic receptor effects.
EvidenceLEADER (HR 0.87), SUSTAIN-6 (HR 0.74), SELECT (20% MACE reduction in obesity), REWIND (HR 0.88), FLOW (renal). Trial design and clinical implications.
ClinicalNICE NG28 & ADA/EASD 2024 consensus. Semaglutide (Ozempic) 0.25→2.0mg; tirzepatide (Mounjaro) 2.5→15mg; liraglutide (Victoza) 0.6→1.8mg titration protocols.
ClinicalSTEP 1: semaglutide 2.4mg −14.9% bodyweight. SURMOUNT-1: tirzepatide 15mg −22.5%. NICE TA875 (Wegovy) & TA1026 (Mounjaro) access criteria.
AdvancedCardioprotective mechanisms: ↑eNOS, ↓NF-κB, ↓plaque inflammation. FLOW trial: 24% slower eGFR decline, 22% ESKD reduction. Albuminuria reduction 20–30%.
Who It's For
Practical guidance for initiating and monitoring GLP-1 RAs in primary care.
ExploreNewsletter
Get notified when new modules launch or landmark trial data becomes available.